Urology Research


Research Conference

This dedicated research conference is held monthly on the second Wednesday of each month from 7:00 – 8:00 a.m. and is dedicated to research discussion, organization and data collection.  Core Urology Faculty will involve each resident in study design, use of national & regional databases, data analysis programs and critical analysis of publications.  Our faculty are also involved in active clinical trials at Erlanger Health System.


Each resident is required to complete research project(s) during their training and submit to local, regional and national conferences for presentation, including the UT Annual Resident Research Week.   


Research Rotation   

The Program Director will also supervise the dedicated 3 month research block during which, within reasonable limits, a research project producing data to publish in a peer reviewed journal or to present at regional and national meetings will be expected.   




** See WHAT's NEW for a list of recent accepted abstracts and resident presentations **






Current Clinical Studies 


Study Title: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States
Principal Investigator: Amar Singh, MD (Current Study)


Study Title: Genomic Markers in Transitional Cell Cancer of the Bladder, Renal Pelvis and Ureter: Sample Acquisition for Methods Development and Discovery
Principal Investigator: Amar Singh, MD (Completed Study)


Study Title: Clinical Validation Of A Urine-Based Assay With Genomic And Epigenomic Markers For Predicting Recurrence During Surveillance For Non-Muscle Invasive Bladder Cancer
Principal Investigator: Amar Singh, MD (Current Study)


Study Title: A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH antagonist) or Leuprolide (LHRH agonist)
Principal Investigator: Amar Singh, MD (Current Study)



Study Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Myrbetriq® in Geriatric Subjects with Overactive Bladder (OAB) 
Principal Investigator: Colin Goudelocke, MD



Study Title: A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1-Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Principle Investigator: Amar Singh, MD (Current Study)


Study Title: A Phase II, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

Principal Investigator: Amar Singh, MD (Current Study)







Updated: 10-02-2018

UT College of Medicine Chattanooga     960 East Third Street, Suite 100     Chattanooga, TN 37403     (800)947-7823, ext 6956     info@utcomchatt.org

Custom CMS and Web Design by Papercut Interactive